Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors by Jappe Annette, Ye DingWei, Shen Lin, Wu YiLong, Xu BingHe, Cherfi Azzeddine, Wang Hui, Yuan RuiRong

Get full text

Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter... by LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua

Get full text

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer by Iwata, Hiroji, Masuda, Norikazu, Kim, Sung-Bae, Inoue, Kenichi, Rai, Yoshiaki, Fujita, Takashi, Chiu, Joanne, Ohtani, Shoichiro, Takahashi, Masato, Miyaki, Toshiko, Lu, Yen-Shen, Xu, Binghe, Yap, Yoon Sim, Bustam, Anita Zarina, Yao, Bin, Zhang, Bo, Bryce, Richard, Chan, Arlene

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition) by Bu Hong, Fan Ying, Fan Zhaoqing, Hu Xichun, Li Man, Li Qiao, Liao Ning, Luo Ting, Nie Jianyun, Pan Yueyin, Qi Xiaowei, Shao Zhimin, Song Guohong, Sun Tao, Teng Yue-e, Tong Zhongsheng, Wang Jiayu, Wang Shusen, Wang Xue, Wang Yongsheng, Wang Zhonghua, Xu Binghe, Xu Ling, Xue Yan, Yang Wentao, Yao Herui, Ying Jianming, Yuan Peng, Zhang Jian, Zhang Qingyuan, Zhang Yongqiang, Zhao Jiuda

Get full text